Premium
Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion‐positive prostate cancers
Author(s) -
Luebke Andreas M.,
Ricken Wiebke,
Kluth Martina,
HubeMagg Claudia,
Schroeder Cornelia,
Büscheck Franziska,
Möller Katharina,
Dum David,
Höflmayer Doris,
Weidemann Sören,
Fraune Christoph,
Hinsch Andrea,
Wittmer Corinna,
Schlomm Thorsten,
Huland Hartwig,
Heinzer Hans,
Graefen Markus,
Haese Alexander,
Minner Sarah,
Simon Ronald,
Sauter Guido,
Wilczak Waldemar,
Meiners Jan
Publication year - 2020
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32957
Subject(s) - prostate cancer , tmprss2 , pca3 , cancer , oncogene , prostate , cancer research , immunohistochemistry , medicine , metastasis , fusion gene , pathology , immunostaining , lymph node , biochemical recurrence , tissue microarray , biology , prostatectomy , cell cycle , disease , gene , biochemistry , covid-19 , infectious disease (medical specialty)
Altered expression of the carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) has been linked to adverse tumor features in various cancer types. To better understand the role of CEACAM1 in prostate cancer, we analyzed a tissue microarray containing tumor spots from 17,747 prostate cancer patients by means of immunohistochemistry. Normal prostate glands showed intense membranous CEACAM1 positivity. Immunostaining was interpretable in 13,625 cancers and was considered high in 28%, low in 43% and absent in 29% of tumors. Low and lost CEACAM1 expression was strongly linked to adverse tumor features including high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, positive surgical margin, a high number of genomic deletions and early biochemical recurrence ( p < 0.0001 each). Subset analysis of molecularly defined cancer subsets revealed that these associations were strongest in V‐ets avian erythroblastosis virus E26 oncogene homolog ( ERG ) fusion‐positive cancers and that CEACAM1 loss was prognostic even in tumors harboring genomic deletions of the phosphatase and tensin homolog tumor suppressor ( p < 0.0001). Multivariate analysis suggested that CEACAM1 analysis can provide independent prognostic information beyond established prognosis parameters at the stage of the initial biopsy when therapy decisions must be taken. In conclusion, loss of CEACAM1 expression predicts poor prognosis in prostate cancer and might provide clinically useful prognostic information particularly in cancers harboring the TMPRSS2:ERG fusion.